Tmunity stops solid tumor CAR-T trial after 2 patients die
Jun 3, 2021 8:40am The setback has led to the winding down of the CART-PSMA-TGFβRDN study. (Image by Dimitris Vetsikas from Pixabay) Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which were first reported by Endpoints, has implications for the broader push to establish cell therapies as treatments for solid tumors. Founded by Carl June, M.D., and Oz Azam, M.D., Tmunity is at the forefron...
Oz Azam University Of Pennsylvania Tmunity Therapeutics Carl June University Of Pennsylvania Carl June
Source: fiercebiotech.com